Online citations, reference lists, and bibliographies.
← Back to Search

A Critical Update On Prognostic And Predictive Biomarkers In Malignant Pleural Mesothelioma

B. Ghanim, Mir Alireza Hoda, T. Klikovits, B. Dome, M. Grusch, M. Filipits, W. Klepetko, W. Berger, B. Hegedűs
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.
This paper references
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1097/SLA.0b013e3182602af4
Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural Mesothelioma: A Retrospective Multicenter Analysis
B. Ghanim (2012)
10.1097/00001622-200303000-00002
Predictive and prognostic factors in malignant pleural mesothelioma
P. Baas (2003)
10.1136/thx.2003.008912
Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma
A. Baldi (2004)
10.1097/JTO.0b013e31822a3740
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
S. Kao (2011)
10.1016/j.ejcts.2008.03.003
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
C. Aigner (2008)
10.1097/JTO.0b013e31823f45c1
Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
D. Pinato (2012)
10.1038/bjc.2013.815
Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
B. Ghanim (2014)
10.1038/bjc.2013.504
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
T. Meniawy (2013)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1097/JTO.0b013e318233d6a9
Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival
Z. G. Zimling (2012)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1200/JCO.2009.25.9275
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
L. Righi (2010)
10.3978/j.issn.2225-319X.2012.10.02
Inflammation in malignant mesothelioma - friend or foe?
Anthony Linton (2012)
10.1097/JTO.0000000000000055
PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy
B. Bitanihirwe (2014)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1016/j.cllc.2012.03.011
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
S. Kao (2013)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1016/j.jtcvs.2012.09.023
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
M. Baud (2013)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1159/000321370
A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma
A. C. Tanrıkulu (2010)
10.1183/09031936.00226111
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1093/jjco/hyq159
Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.
S. Nojiri (2011)



Semantic Scholar Logo Some data provided by SemanticScholar